InDex Pharmaceuticals Holding AB
STO:FLERIE
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
8.8
55.8
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one FLERIE stock under the Base Case scenario is 5.853 SEK. Compared to the current market price of 46.915 SEK, InDex Pharmaceuticals Holding AB is Overvalued by 88%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
InDex Pharmaceuticals Holding AB
Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
Historical valuation for FLERIE cannot be conducted due to limitations such as insufficient data or other constraints.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
InDex Pharmaceuticals Holding AB
Balance Sheet Decomposition
InDex Pharmaceuticals Holding AB
Current Assets | 1.1B |
Cash & Short-Term Investments | 911.3m |
Receivables | 140.9m |
Other Current Assets | 12.4m |
Non-Current Assets | 3.2B |
Long-Term Investments | 100k |
PP&E | 1.1m |
Other Non-Current Assets | 3.2B |
Current Liabilities | 23.2m |
Accounts Payable | 6.7m |
Accrued Liabilities | 5.4m |
Other Current Liabilities | 11.1m |
Non-Current Liabilities | 3.5m |
Long-Term Debt | 500k |
Other Non-Current Liabilities | 3m |
Earnings Waterfall
InDex Pharmaceuticals Holding AB
Revenue
|
100k
SEK
|
Cost of Revenue
|
-92.1m
SEK
|
Gross Profit
|
-92m
SEK
|
Operating Expenses
|
-110.8m
SEK
|
Operating Income
|
-202.8m
SEK
|
Other Expenses
|
-66.7m
SEK
|
Net Income
|
-269.5m
SEK
|
Free Cash Flow Analysis
InDex Pharmaceuticals Holding AB
SEK | |
Free Cash Flow | SEK |
FLERIE Profitability Score
Profitability Due Diligence
InDex Pharmaceuticals Holding AB's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
InDex Pharmaceuticals Holding AB's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
FLERIE Solvency Score
Solvency Due Diligence
InDex Pharmaceuticals Holding AB's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
InDex Pharmaceuticals Holding AB's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FLERIE Price Targets Summary
InDex Pharmaceuticals Holding AB
According to Wall Street analysts, the average 1-year price target for FLERIE is 47.26 SEK with a low forecast of 27.27 SEK and a high forecast of 71.4 SEK.
Dividends
Current shareholder yield for FLERIE is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one FLERIE stock under the Base Case scenario is 5.853 SEK.
Compared to the current market price of 46.915 SEK, InDex Pharmaceuticals Holding AB is Overvalued by 88%.